Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Advances in Microarray Technology

Advances in Microarray Technology Keynote Speakers



Carl Borrebaeck
Professor and Deputy Vice Chancellor, Lund University

Prof. Carl Borrebaeck is chairman of the Department of Immunotechnology, Lund University and program Director of the Strategic Center for Translational Cancer Research – CREATE Health (www.createhealth.lth.se). He received the first chair as professor of Immunotechnology in Scandinavia 1989. His main research interests are cancer proteomics, for early detection and prognosis, and antibody engineering, for the generation of human therapeutic antibodies. He is a permanent member of the Royal Swedish Academy of Engineering Sciences and deputy vice chancellor of Lund University, with a special responsibility for its innovation system. He received the AKZO Nobel Science Award 2009, for his contributions to cancer proteomics and antibody-based therapy. Prof. Borrebaeck spent a sabbatical year at the Oklahoma Medical Research Foundation 1996-97 and did his post-doctoral training at the University of California in Davis. He received his Doctor of Science (D.Sc.) in 1979. His research has resulted in several spin-out companies, such as BioInvent International AB, Alligator Bioscience AB, Immunovia AB and SenzaGen AB.

Carl Borrebaeck Image
 

Michael Pawlak
Head, University of Tuebingen

Dr. Michael Pawlak joined the NMI in 2005 and is heading the Department of Biochemistry and Protein Profiling. In a multidisciplinary environment, scientists develop advanced assay systems and applications for industrial partners. Dr. Pawlak's research is focused on the application of microarrays for proteomic and cancer research, including the study of mechanisms of disease and drug action, and the identification of biomarkers for use in personalized medicine. He is offering protein profiling services to pharmaceutical industry and clinical research using Reverse Phase Protein Arrays for the analysis of protein signaling networks. Before Dr. Pawlak was at Novartis Pharma AG and co-founder of Zeptosens AG, and was pioneering sensitive planar waveguide technology for use with Reverse Phase Protein Arrays.

Michael Pawlak Image
 

Add to Calendar ▼2012-03-28 00:00:002012-03-29 00:00:00Europe/LondonAdvances in Microarray TechnologyAdvances in Microarray Technology in Edinburgh, ScotlandEdinburgh, ScotlandSELECTBIOenquiries@selectbiosciences.com